Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 285

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

Long, Georgina V., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Daud, Adil, Gonzalez, Rene, Sosman, Jeffrey A., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Kefford, Richard F., Lawrence, Donald, Kudchadkar, Ragini, Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Puzanov, Igor, Ibrahim, Nageatte, Sun, Peng, Cunningham, Elizabeth, Kline, Amy S., Del Buono, Heather, McDowell, Diane Opatt, Patel, Kiran, Flaherty, Keith T.·2016·Journal of Clinical Oncology

Abstract

Purpose: To report the overall survival (OS) and clinical characteristics of BRAF inhibitor–naive long-term responders and survivors treated with dabrafenib plus trametinib in a phase I and II study of patients with BRAF V600 mutation–positive metastatic melanoma. Methods: BRAF inhibitor–naive patients treated with dabrafenib 150 mg twice daily plus trametinib 2 mg daily (the 150/2 group) from the non–randomly assigned (part B) and randomly assigned (part C) cohorts of the study were analyzed for progression-free and OS separately. Baseline characteristics and factors on treatment were analyzed for associations with durable responses and OS. Results: For BRAF inhibitor–naive patients in the 150/2 groups (n = 78), the progression-free survival at 1, 2, and 3 years was 44%, 22%, and 18%, respectively, for part B (n = 24) and 41%, 25%, and 21%, respectively, for part C (n = 54). Median OS was 27.4 months in part B and 25 months in part C. OS at 1, 2, and 3 years was 72%, 60%, and 47%, respectively, for part B and 80%, 51%, and 38%, respectively, for part C. Prolonged survival was associated with metastases in fewer than three organ sites and lower baseline lactate dehydrogenase. OS at 3 years was 62% in patients with normal baseline lactate dehydrogenase and 63% in patients with a complete response. Conclusion: Dabrafenib plus trametinib results in a median OS of more than 2 years in BRAF inhibitor–naive patients with BRAF V600 mutation–positive metastatic melanoma, and approximately 20% were progression free at 3 years. Durable responses occurred in patients with good prognostic features at baseline, which may be predictive.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.62.9345

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 285

Metadata

Authors
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., Sosman, J. A., Hamid, O., Schuchter, L., Cebon, J., Kefford, R. F., Lawrence, D., Kudchadkar, R., Burris, H. A., Falchook, G. S., Algazi, A., Lewis, K., Puzanov, I., Ibrahim, N., Sun, P., Cunningham, E., Kline, A. S., Del Buono, H., McDowell, D. O., Patel, K., & Flaherty, K. T.
Venue
Journal of Clinical Oncology
Published
2016-03-10
Volume
34
Issue
8
Pages
871-878
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2254594392
Cited by
285
References
28
FWCI
24.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. https://app.cochat.ai/papers/10.1200/jco.2015.62.9345
The paper
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., Sosman, J. A., Hamid, O., Schuchter, L., Cebon, J., Kefford, R. F., Lawrence, D., Kudchadkar, R., Burris, H. A., Falchook, G. S., Algazi, A., Lewis, K., Puzanov, I., Ibrahim, N., . . . Flaherty, K. T. (2016). Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.62.9345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.